Canakinumab for Atherosclerotic Disease.
作者信息
O'Neill Luke A, Cooper Matthew A
机构信息
Trinity College Dublin, Dublin, Ireland
University of Queensland, Brisbane, QLD, Australia
出版信息
N Engl J Med. 2018 Jan 11;378(2):198-9. doi: 10.1056/NEJMc1714635.
PMID:29322757
Abstract
摘要
相似文献
1
Canakinumab for Atherosclerotic Disease.卡那单抗用于动脉粥样硬化疾病
N Engl J Med. 2018 Jan 11;378(2):198-9. doi: 10.1056/NEJMc1714635.
2
Canakinumab for Atherosclerotic Disease.
N Engl J Med. 2018 Jan 11;378(2):197. doi: 10.1056/NEJMc1714635.
3
Canakinumab for Atherosclerotic Disease.
N Engl J Med. 2018 Jan 11;378(2):196-7. doi: 10.1056/NEJMc1714635.
4
Canakinumab for Atherosclerotic Disease.
N Engl J Med. 2018 Jan 11;378(2):199. doi: 10.1056/NEJMc1714635.
5
Canakinumab for Atherosclerotic Disease.卡那单抗用于治疗动脉粥样硬化疾病。
N Engl J Med. 2018 Jan 11;378(2):199-200. doi: 10.1056/NEJMc1714635.
6
Canakinumab for Atherosclerotic Disease.卡那单抗用于动脉粥样硬化疾病
N Engl J Med. 2018 Jan 11;378(2):197-8. doi: 10.1056/NEJMc1714635.
7
Canakinumab for secondary prevention of atherosclerotic disease.卡那奴单抗用于动脉粥样硬化疾病的二级预防。
Expert Opin Biol Ther. 2018 Feb;18(2):215-220. doi: 10.1080/14712598.2018.1420776. Epub 2017 Dec 27.
8
Multiple testing in the 'Canakinumab in atherosclerosis' trial: correction required?“卡那单抗治疗动脉粥样硬化”试验中的多重检验：是否需要校正？
Clin Exp Rheumatol. 2017 May-Jun;35 Suppl 104(2):24. Epub 2017 Apr 27.
9
Targeting arterial wall sulfated glycosaminoglycans in rabbit atherosclerosis with a mouse/human chimeric antibody.用小鼠/人嵌合抗体靶向兔动脉粥样硬化中的动脉壁硫酸化糖胺聚糖。
MAbs. 2014;6(5):1340-6. doi: 10.4161/mabs.29970. Epub 2014 Oct 30.
10
Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.卡那单抗用于治疗活动性全身型幼年特发性关节炎。
Expert Rev Clin Pharmacol. 2016 Aug;9(8):1015-24. doi: 10.1080/17512433.2016.1204910. Epub 2016 Jul 6.
引用本文的文献
1
Neutrophil-Derived S100A8/A9 Amplify Granulopoiesis After Myocardial Infarction.中性粒细胞衍生的 S100A8/A9 在心肌梗死后增强粒细胞生成。
Circulation. 2020 Mar 31;141(13):1080-1094. doi: 10.1161/CIRCULATIONAHA.119.043833. Epub 2020 Jan 16.
Zotero 插件